Article

Computational Determination of Toxicity Risks Associated with a Selection of Approved Drugs having Demonstrated Activity Against COVID- 19

2021-05-21

Abstract excerpt

<h4>Background: </h4> The emergence and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) at late 2019 has caused a devastating global pandemic of the severe pneumonia-like disease coronavirus disease 2019 (COVID-19). Although vaccines have been and are being developed, they are not accessible to everyone and not everyone can receive these vaccines. Also, it typically takes more than 10...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 03c85e81-6757-5968-9920-5402ad0c73dc
DOI: 10.21203/rs.3.rs-403464/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Computational Determination of Toxicity Risks Associated with a Selection of Approved Drugs having Demonstrated Activity Against COVID- 19DOI 10.21203/rs.3.rs-403464/v1Read

Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugsSemantic proximity Read

Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus InfectionsSemantic proximity Read

An Integrative in Silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main ProteaseSemantic proximity Read

Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico studySemantic proximity Read

Prediction of repurposed drugs for treating lung injury in COVID-19Semantic proximity Read

Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19Semantic proximity Read

Ontological and Bioinformatic Analysis of Anti-Coronavirus Drugs and Their Implication for Drug Repurposing against COVID-19Semantic proximity Read

In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic DataSemantic proximity Read

DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHESSemantic proximity Read

Drug Repurposing of potential drug targets for treatment of COVID-19Semantic proximity Read

A Network-Biology Led Computational Drug Repurposing Strategy to Prioritize Therapeutic Options for COVID-19Semantic proximity Read

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19Semantic proximity Read